740-Y-P-DataSheet-MedChemExpress
鱼酚氧化酶(PO)试剂盒说明书含量
鱼酚氧化酶(PO)酶联免疫分析(ELISA)试剂盒使用说明书本试剂仅供研究使用目的：本试剂盒用于测定鱼血清，血浆，及相关液体样本中酚氧化酶(PO)的含量。
实验原理：本试剂盒应用双抗体夹心法测定标本中鱼酚氧化酶(PO)水平。
用纯化的鱼酚氧化酶(PO)抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入酚氧化酶(PO)再与HRP标记的酚氧化酶(PO)抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB 显色。
TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的酚氧化酶(PO)呈正相关。
用酶标仪在450nm波长下测定吸光度（OD值），通过标准曲线计算样品中鱼酚氧化酶(PO)浓度。
试剂盒组成：试剂盒组成48孔配置96孔配置保存说明书1份1份封板膜2片（48）2片（96）密封袋1个1个酶标包被板1×481×962-8℃保存标准品：900pg/ml0.5ml×1瓶0.5ml×1瓶2-8℃保存标准品稀释液 1.5ml×1瓶 1.5ml×1瓶2-8℃保存酶标试剂3ml×1瓶6ml×1瓶2-8℃保存样品稀释液3ml×1瓶6ml×1瓶2-8℃保存显色剂A液3ml×1瓶6ml×1瓶2-8℃保存显色剂B液3ml×1瓶6ml×1瓶2-8℃保存终止液3ml×1瓶6ml×1瓶2-8℃保存浓缩洗涤液（20ml×20倍）×1瓶（20ml×30倍）×1瓶2-8℃保存样本处理及要求：1.血清：室温血液自然凝固10-20分钟，离心20分钟左右（2000-3000转/分）。
仔细收集上清，保存过程中如出现沉淀，应再次离心。
2.血浆：应根据标本的要求选择EDTA或柠檬酸钠作为抗凝剂，混合10-20分钟后，离心20分钟左右（2000-3000转/分）。
艾森生物 实验室耗材和试剂 目录t
21127-030
P0018 31458
20W 500ml 500ml 100ml PL009 PL017 353002 3516
11644807001
2227S/100ul 3175S/100ul 7002s/100ul 7004s/100ul 9803s/15ml G7126-1KG
胎牛血清FBS MEM
FX 384 30ul 枪头
Horse serum马血清
DMSO
PMSF
25ml移液管
DMEM 细胞筛网 70um
细胞培养皿 65×15mm
384孔板
真空抽气泵
BSA牛血清蛋白
EGF Receptor (D38B1) XP® Rabbit mAb
western 一抗二抗去除液（弱碱性）
96孔细胞培养板 细胞网筛
25ml移液管 96孔板
无酚红1640 0.1-20ul排枪枪头 10-250ul排枪枪头 1ml盒装蓝色枪头 Trypsin EDTA,0.05%
DMSO 医用酒精棉球
医用酒精棉 麻面无粉手套 1ml灭菌盒装蓝枪头
DMEM L-15 384 HT assay plates
P3563-10PAK
PL017
SM0671/2x250ul
PL009 4685s/100ul 9271s/100ul
9101s/200ul
9102s/200ul 7002s/100ul 7004s/100ul 9803s/15ml
3777s/100ul
21127-022
11644807001 11966-025 6570 SD6031 华东 CU50
Gibco 华东 华东 Roche Gibco CORNING 上海生工 M号 中新 迪申 sigma AXYGEN Gibco
740 Y-P_AbMole中国_CAS号1236188-16-1_M9389说明书Protocol
Concentration / Solvent Volume / Mass
1 mg
5 mg
10 mg
1 mM
0.3057 mL
1.5287 mL
3.0574 mL
5 mM
0.0611 mL
0.3057 mL
0.6115 mL
10 mM
0.0306 mL
0.1529 mL
0.3057 mL
参考文献
Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide. Derossi D, et al. Biochem Biophys Res Commun. 1998 Oct 9;251(1):148-52. PMID: 9790922.
不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）
小鼠
大鼠
兔
豚鼠
仓鼠
狗
重量 (kg) 体表面积 (m2)
0.02 0.007
0.15 0.025
1.8
0.4
0.08
10
0.15
0.05
0.02
0.5
Km 系数
3
6
12
8
5
20
动物 A (mg/kg) = 动物 B (mg/kg) × 动物 B的Km系数 动物 A的Km系数
例如，依据体表面积折算法，将白藜芦醇用于小鼠的剂量22.4 mg/kg 换算成大鼠的剂量，需要将22.4 mg/kg 乘以小鼠的Km系数（3）， 再除以大鼠的Km系数（6），得到白藜芦醇用于大鼠的等效剂量为11.2 mg/kg。
储备液配制 以下数据基于产品分子量，对于特殊产品，请参照COA中的储备液配制条件和说明进行操作。
YM-155_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:YM155 (Sepantronium bromide) is a novel small molecule survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.IC50 Value: 0.54 nMTarget: SurvivinIn vitro: YM155 is not sensitive to survivn gene promoter–driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC–3 and PPC–1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c–IAP2, XIAP, Bcl–2, Bcl–xL, Bad,α–actin, and β–tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC–3 and PPC–1 with a concomitant increase in caspase–3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC–3, PPC–1, DU145, TSU–Pr1, 22Rv1, SK–MEL–5 and A375 with IC50 from 2.3 to 11 nM, respectively [1]. YM155 increases thesensitivity of NSCLC cells to γ–radiation. The combination of YM155 and γ–radiation increases both the number of apoptotic cells and the activity of caspase–3. YM155 delays the repair of radiation–induced double–strand breaks in nuclear DNA [2].In vivo: YM155 completely inhibits the tumor growth of PC–3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue.Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC–3 orthotopic xenografts [1]. The combination therapy with YM155 and γ–radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice [2].PROTOCOL (Extracted from published papers and Only for reference)Enzyme assay [1]:The caspase–3 activity was measured with a CPP32/Caspase–3 Fluometric Protease Assay Kit (MBL) according to the manufacturer's instructions. After incubation with YM155 for 48 h, PC–3 and PPC–1 cells were lysed in 100 μL of a cell lysis buffer (provided with the kit) and equal volumes (50 μL) of cell lysate were obtained (100 μg of protein). After addition of 2× reaction buffer, the mixture was added to a black 96–well plate. The DEVD–AFC substrate (appended with the kit) was then added at 5 mL/well and the mixture incubated at 37°C for 30 min. Fluorescence emissions were quantified with a spectrofluorometer at an excitation wavelength of 390nm and an emission wavelength of 460 nm.Cell assay(growth inhibition) [1]:The antiproliferative activity of YM155 was measured by the method used at the National Cancer Institute. After treatment with YM155for 48 h, the cell count was determined by sulforhodamine B assay. The GI50 value was calculated by logistic analysis, which is thedrug concentration resulting in a 50% reduction in the net protein increase (as measured by sulforhodamine B staining) in control cells during the drug incubation. The assay was done in triplicate, and the mean GI50 value was obtained from the results of fourProduct Name:YM–155Cat. No.:HY-10194CAS No.:781661-94-7Molecular Formula:C 20H 19BrN 4O 3Molecular Weight:443.29Target:Survivin; Autophagy Pathway:Apoptosis; Autophagy Solubility:DMSO: 10.66 mg/mLindependent assays.Animal administration [1]:Five–week–old male nude mice (BALB/c nu/nu) were purchased from Charles River Japan, Inc. PC–3 cells (2 × 106–3 × 106) were injected into the flanks of the mice and allowed to reach a tumor volume of >100 mm3 in tumor volume (length × width2 × 0.5). YM155 was s.c. administered as a 3–day continuous infusion per week for 2 weeks using an implanted micro–osmotic pump (Alzet model 1003D, Durect) or i.v. administered five times a week for 2 weeks. The percentage of tumor growth inhibition 14 days after initial YM155 administration was calculated for each group using the following formula: MTV = 100 × {1–[(MTV of the treated group on day 14)–(MTV of the treated group on day 0)] / [(MTV of the control group on day 14)–(MTV of the control group on day 0)]}, where MTV is mean tumor volume. For both the frozen tumors and plasma samples, survivin expression levels were analyzed by Western blotting and YM155 drug concentration by high–performance liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) using validated methods.References:[1]. Nakahara T, et al. YM155, a novel small–molecule survivin suppressant, induces regression of established human hormone–refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014–21.[2]. Iisa T, et al. Radiosensitizing effect of YM155, a novel small–molecule survivin suppressant, in non–small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496–504.[3]. Guo K, et al. A combination of YM–155, a small molecule survivin inhibitor, and IL–2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137–47.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
美国贝克曼库尔特流式细胞分析仪
美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。
但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。
在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。
75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。
淋巴瘤和CLD相似，需要至少12-16种单抗。
对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。
其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。
几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。
但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。
大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。
抗体的质量控制是实验的关键环节。
抗体的质量包括其特异性、灵敏度、精密度。
东洋纺快速Taq HS染料混合物使用手册 101盒说明书
manual Quick Taq HS Dye Mix 1306 F1138K Quick Taq HS DyeMixDTM-101 100 reactionsStore at -20°C Contents[1] Introduction[2] Components[3] Primer design[4] Analysis and Cloning of PCR products[5] Protocol1. Standard reaction setup2. Cycling conditions[6] Examples[7] TroubleshootingCAUTIONAll reagents in this kit are intended for research purposes. Do not use for diagnosis or clinical purposes. Please observe general laboratory precaution and utilize safety while using this kit.JAPAN CHINATOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140www.toyobo.co.jp/e/bio1JAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 1 ] Introduction[ 2 ] Components[ 3 ] Primer Design[ 4 ] Analysis andCloning of PCR productsDescriptionQuick Taq HS DyeMix is a Taq-based 2× master mix PCR reagent that contains anelectrophoresis dye (BPB; bromophenol blue) and anti-Taq antibodies for hot start PCR. This reagent contains all components for PCR except primers and template DNA. This reagent shows specific and efficient amplification. The amplified products can be directly loaded in the wells of agarose or acrylamide gels.Features-As this reagent contains bromophenol blue (BPB) as an electrophoresis dye; the PCR products can be analyzed directly with an agarose or acrylamide gel.-This reagent exhibits greater PCR performance than conventional rTaq DNA polymerase.-This reagent contains anti-Taq antibodies for hot start PCR. Hot start technology realizes highly specific and sensitive PCR.-This reagent is stable for at least three months at 4°C. No decrease in reaction efficiency is observed following 30 freeze-thaw cycles.-This reagent is suitable for a colony-direct PCR (see [6], Example 2).This reagent includes the following components for 100 reactions, 50 μl total reaction volume:2× Quick Taq HS DyeMix1.25ml× 2*In the case of the long-term storage (>3 months), this reagent should be stored at-20°C.Primers should be 22–35 bases long, with a melting temperature (Tm) > 60°C.-As this reagent contains bromophenol blue (BPB) as an electrophoresis dye and by adjusting its relative density, the PCR products can be applied directly to an agarose or acrylamide gel.-The PCR products can be cloned using general TA cloning technology.-The PCR products can be used as templates for sequencing after an appropriate treatment.JAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 5 ] Protocol[ 6 ] Examples1. Standard reactionBefore preparing the reaction mixture, the master mix solution should be completely thawed. *For the PCR reaction, thin-wall tubes are recommended. A total reaction volume of 50 μl is also recommended.2. PCR cycle conditionsExample 1. Amplification of the human p53 gene (2.9 kb)The human p53 gene (2.9 kb) was amplified using 50 ng of human genomic DNA.Quick Taq HS DyeMix successfully amplified the targets.Reaction volume 50 μl 20 μl Final concentrationAutoclaved, distilled water X μl X μl 2x Quick Taq HS DyeMix 25 μl 10 μl 1 × 10 pmol /μl Primer #1 1.0 μl 0.4 μl 0.2 μM 10 pmol /μl Primer #2 1.0 μl 0.4 μl 0.2 μM Template DNAY μlY μlGenomic DNA -200 ng / 50 μl Plasmid DNA -50 ng / 50 μl E. coli colonyTotal 50 μl 20 μl3-step cyclePredenaturation: 94°C , 2min. Denaturation: 94°C , 30sec. °C , 30sec. Extension: 68°C , 1min. /kb 2-step cyclePredenaturation: 94°C , 2min. Denaturation: 94°C , 30sec. Extension: 68°C , 1min. /kbJAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 7 ] Trouble shootingExample 2. Insert amplification by a colony-direct PCRThe inserts were amplified using Quick Taq HS DyeMix with universal primers from E. coli DH5α colonies bearing pTA2 plasmid (insert size: 500 bp). Quick Taq HS DyeMix successfully and efficiently amplified all targets.SymptomCauseSolutionNo PCR product / low yieldCycling conditions are not suitable.Increase the number of cycles by 2-5 cycles. Primer is not good.Check the quality of the primers. Redesign the primers.Template DNA is ofinsufficient quality and/or quantity.Check the quality of the template DNA. Increase the amount of the template DNA Too much sample Excessive amounts of bacterial cells may inhibit amplification. Decrease the sample volume. Smearing / Extra bandCycling conditions are not suitable.Decrease the number of cycles by 2-5 cycles.Primer concentration is not appropriate Optimize the primer concentration to around 0.1-0.2 μM.Annealing temperature is too low. Optimize the annealing temperature to around 55°C -65°C . Primer is not good. Check the quality of the primers. Redesign the primers. Too much template DNA Reduce the amount of template DNA。
740_Y-P_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:740 Y–P (PDGFR 740Y–P) is a potent and cell permeable PI3K activator.IC50 & Target: PI3K [1]In Vitro: 740 Y–P is a synthetic biotinylated peptide consisting of the 16–amino acid sequence derived from the third helix of the Antennapedia protein in tandem with a 9 amino acid phosphopeptide mimetic of the high affinity p85 binding site on the PDGFreceptor. 740 Y–P readily binds GST fusion proteins containing both the N– and C– terminal SH2 domains of p85. 740 Y–P fails to bind GST alone, or a GST fusion protein containing the N– terminal SH2 domain of PLCg and shows relatively weak binding of a GST fusion proteins containing the SH2 domain of Grb2. The 740 Y–P peptide is also able to specifically interact with p85 in cell lysates as shown by affinity precipitation. 740 Y–P stimulates mitogenesis at the lowest concentration tested (1 mg/mL). The peptide stimulates mitogenesis in both the presence and absence of serum (0.5%), and in the former instance a maximal response observed at 50mg/mL. 740Y–P peptide to stimulate mitogenesis is highly specific and not a general feature of a cell permeable SH2 domain binding peptides [1]. 740 Y–P potently inhibits the PI3K pathway. It remarkably reduces the number of M6PR–positive vacuoles induced by the sucrose treatment [2].In Vivo: 740 Y–P is not only internalised in living cells but can also interact with p85 in vivo .[1]PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[1]Following serum starvation, C2 cells are cultured in the presence of the PDGFR 740Y–P peptide at the givenconcentrations (0, 1, 10, 100 μg/mL) for 48 h. The mitogenic response is assessed by measurement of the percentage of cells in S–phase [1].References:[1]. Derossi D, et al. Stimulation of mitogenesis by a cell–permeable PI 3–kinase binding peptide.[2]. Bin BH, et al. Hyperosmotic stress reduces melanin production by altering melanosome formation. PLoS One. 2014 Aug 29;9(8):e105965.Product Name:740 Y–P Cat. No.:HY-P0175CAS No.:1236188-16-1Molecular Formula:C141H222N43O39PS3Molecular Weight:3270.70Target:PI3K Pathway:PI3K/Akt/mTOR Solubility:H 2OCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
740_Y-P_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-15-2018Print Date:Jan.-15-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :740 Y-PCatalog No. :HY-P0175CAS No. :1236188-16-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word No data availableHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:740YPDGFR; PDGFR 740Y–PFormula:C141H222N43O39PS3Molecular Weight:3270.70CAS No. :1236188-16-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-80°C 2 years-20°C 1 yearIn solvent-80°C 6 months-20°C 1 month7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。